Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

RITONAVIR

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (J05A, J05AE) — coverage varies; not interchangeable

  • Atazanavir (Reyataz): general benefit, Not a benefit
  • Darunavir (Prezista): general benefit, Not a benefit
  • Fosamprenavir (Telzir): general benefit
  • Nelfinavir (Viracept): general benefit
  • Abacavir + lamivudine + zidovudine (Trizivir): general benefit
  • Abacavir (Ziagen): general benefit

46 more in the class list below

Auro-Ritonavir · DIN 02523620 · 100mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Ritonavir · DIN 02523620 Manufacturer: Auro Pharma Inc.; listing date 2022-10-31 Health Canada: Marketed since 2022-09-08 · brand AURO-RITONAVIR · ATC J05AE03 RITONAVIR · form Tablet · route Oral · ingredients RITONAVIR 100 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Ritonavir: Formulary list price $1.1745/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.1745 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101271 · Verify on the e-Formulary ↗ (DIN 02523620)

Source record
DIN 02523620: Auro-Ritonavir Raw flags: sec3=Y Item: 081800350; group id 108; item number 0190; lccId None; manufacturer id AUR Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $1.1745; ministry $1.1745 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02523620 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101271
Interchangeable products
Norvir · DIN 02357593 · $1.1745
Shortage status: resolved shortage (ended 2024-11-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02523620
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Norvir · DIN 02357593 · 100mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Norvir · DIN 02357593 Manufacturer: Abbott Laboratories Limited; listing date 2012-02-29 Health Canada: Marketed since 2014-04-30 · brand NORVIR · ATC J05AE03 RITONAVIR · form Tablet · route Oral · ingredients RITONAVIR 100 MG · company Abbvie corporation · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $1.1745 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84270 · Verify on the e-Formulary ↗ (DIN 02357593)

Source record
DIN 02357593: Norvir Raw flags: sec3=Y Item: 081800350; group id 108; item number 0190; lccId None; manufacturer id ABB Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $1.5660; ministry $1.1745 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02357593 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84270
Interchangeable products
Auro-Ritonavir · DIN 02523620 · $1.1745
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02357593
Shortage record checked 2026-09-13T08:10:21.292534+00:00

LOPINAVIR & RITONAVIR

Form:

3 of 3 products shown

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (J05A, J05AE) — coverage varies; not interchangeable

  • Atazanavir (Reyataz): general benefit, Not a benefit
  • Darunavir (Prezista): general benefit, Not a benefit
  • Fosamprenavir (Telzir): general benefit
  • Nelfinavir (Viracept): general benefit
  • Abacavir + lamivudine + zidovudine (Trizivir): general benefit
  • Abacavir (Ziagen): general benefit

46 more in the class list below

Kaletra · DIN 02243644 · 80mg/mL & 20mg/mL · oral liquid

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Kaletra · DIN 02243644 Manufacturer: AbbVie Corporation; listing date 2001-10-11 Health Canada: Marketed since 2014-06-09 · brand KALETRA · ATC J05AR10 LOPINAVIR AND RITONAVIR · form Solution · route Oral · ingredients LOPINAVIR 400 MG/5ML, RITONAVIR 100 MG/5ML · company Abbvie corporation · schedule Prescription
Check this DIN again · Health Canada product record

Kaletra: Formulary list price $2.4635/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.4635 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67570 · Verify on the e-Formulary ↗ (DIN 02243644)

Source record
DIN 02243644: Kaletra Raw flags: sec3=Y Item: 081800061; group id 98; item number 0171; lccId None; manufacturer id ABV Source form: O/L; strength: 80mg/mL & 20mg/mL Recorded listing: General benefit Source prices (unrounded): $2.4635; ministry $2.4635 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02243644 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67570
Shortage status: resolved shortage (ended 2022-05-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02243644
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Kaletra · DIN 02312301 · 100mg & 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Kaletra · DIN 02312301 Manufacturer: AbbVie Corporation; listing date 2009-04-01 Health Canada: Marketed since 2014-11-25 · brand KALETRA · ATC J05AR10 LOPINAVIR AND RITONAVIR · form Tablet · route Oral · ingredients RITONAVIR 25 MG, LOPINAVIR 100 MG · company Abbvie corporation · schedule Prescription
Check this DIN again · Health Canada product record

Kaletra: Formulary list price $3.0489/unit (unit not stated in source; not the patient's cost)

Ministry pays: $3.0489 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79781 · Verify on the e-Formulary ↗ (DIN 02312301)

Source record
DIN 02312301: Kaletra Raw flags: sec3=Y Item: 081800110; group id 98; item number 0172; lccId None; manufacturer id ABV Source form: Tab; strength: 100mg & 25mg Recorded listing: General benefit Source prices (unrounded): $3.0489; ministry $3.0489 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02312301 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79781
Shortage status: resolved shortage (ended 2021-06-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02312301
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Kaletra · DIN 02285533 · 200mg & 50mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Kaletra · DIN 02285533 Manufacturer: AbbVie Corporation; listing date 2007-09-04 Health Canada: Marketed since 2015-01-14 · brand KALETRA · ATC J05AR10 LOPINAVIR AND RITONAVIR · form Tablet · route Oral · ingredients RITONAVIR 50 MG, LOPINAVIR 200 MG · company Abbvie corporation · schedule Prescription
Check this DIN again · Health Canada product record

Kaletra: Formulary list price $6.0979/unit (unit not stated in source; not the patient's cost)

Ministry pays: $6.0979 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77104 · Verify on the e-Formulary ↗ (DIN 02285533)

Source record
DIN 02285533: Kaletra Raw flags: sec3=Y Item: 081800098; group id 98; item number 0173; lccId None; manufacturer id ABV Source form: Tab; strength: 200mg & 50mg Recorded listing: General benefit Source prices (unrounded): $6.0979; ministry $6.0979 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02285533 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77104
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02285533
Shortage record checked 2026-09-13T08:10:21.292534+00:00

NIRMATRELVIR & RITONAVIR

All products: Limited Use (codes 673, 674, 675)

Other products in the same Health Canada class (J05A, J05AE) — coverage varies; not interchangeable

  • Atazanavir (Reyataz): general benefit, Not a benefit
  • Darunavir (Prezista): general benefit, Not a benefit
  • Fosamprenavir (Telzir): general benefit
  • Nelfinavir (Viracept): general benefit
  • Abacavir + lamivudine + zidovudine (Trizivir): general benefit
  • Abacavir (Ziagen): general benefit

46 more in the class list below

Paxlovid · DIN 02524031 · 150mg & 100mg · tablets, 30-pack

Limited Use — Reason for Use code 673, 674, 675 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 673, 674, 675 required
Write on scriptLU code 673, 674, 675 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 673, 674, 675
Reason for Use code 673 For the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in patients 65 years of age or older with: - a positive result from direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing (either using rapid antigen test or PCR), and - symptoms present for 5 days or fewer. Paxlovid (DIN: 02527804) is intended for patients with renal impairment or on dialysis. If Paxlovid (DIN: 02524031) is being dispensed for such patients, it requires dose adjustment. Treatment decisions should be individualized based on the prescriber's assessment of patient risk because not all medical or social vulnerabilities carry the same risk. Prescribers should consult Ontario Health Recommendations for Antiviral Therapy for Adults with Mild to Moderate COVID-19 (April 2024). Pharmacists and prescribers should be informed of and stay current with a drug product's official indications in accordance with Health Canada's approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for Paxlovid. The Executive Officer's funding of drug products is informed by advice from expert committees that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products. Note: The funded treatment is one dose pack* for a treatment duration of 5 days. * Dose pack for DIN: 02524031 is package of 30 tablets divided in 5 daily-dose blister cards containing 4 nirmatrelvir tablets (150mg each) and 2 ritonavir tablets (100mg each). * Dose pack for DIN: 02527804 is a package of 20 tablets divided in 5 daily-dose blister cards containing 2 nirmatrelvir tablets (150mg each) and 2 ritonavir tablets (100mg each). Coverage limit: LU Authorization Period: 5 days to align with funded treatment duration. Reason for Use code 674 For the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in immunocompromised* patients 18 years of age or older regardless of vaccine status or prior COVID-19 infections with: - a positive result from direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing (either using rapid antigen test or PCR), and - symptoms present for 5 days or fewer. * Prescribers should consult Ontario Health Recommendations for Antiviral Therapy for Adults with Mild to Moderate COVID-19 (April 2024). Examples of immunocompromised include: - Advanced untreated human immunodeficiency virus (HIV) or treated HIV with a CD4 count equal or less than 200 per mm3 or CD4 fraction equal or less than 15% - Bone marrow or stem cell transplant - Solid organ transplant - Have active hematological malignancy or recently received treatment for hematological malignancy - E.g., have received treatment with any anti-CD20 agents or B-cell depleting agents in the last 2 years - Chimeric antigen receptor (CAR) T-cell therapy in the last 6 months - Treatment for cancer (including solid tumors), limited to: systemic therapy in the last 6 months (e.g., chemotherapy, molecular therapy, immunotherapy, targeted therapies, monoclonal antibodies, excluding those receiving adjunctive hormonal therapy only) or radiation therapy in the last 3 months - Prednisone use equal to or greater than 20mg/day (or corticosteriod equivalent) for 14 days or more, or other moderately or severely immunosuppressive therapies (e.g., alkylating agents) - Primary immunodeficiencies. For example: - Hypogammaglobulinemia - Combined immune deficiencies affecting T-cells - Immune dysregulation (e.g., familial hemophagocytic lymphohistiocytosis) - Type 1 interferon defects caused by a genetic primary immunodeficiency disorder or secondary to anti-interferon autoantibodies - Diagnosed by an immunologist and requires ongoing immunoglobulin replacement therapy (IVIg or SCIg) - Primary immunodeficiency with a confirmed genetic cause (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome) Paxlovid (DIN: 02527804) is intended for patients with renal impairment or on dialysis. If Paxlovid (DIN: 02524031) is being dispensed for such patients, it requires dose adjustment. Treatment decisions should be individualized based on the prescriber's assessment of patient risk because not all medical or social vulnerabilities carry the same risk. Pharmacists and prescribers should be informed of and stay current with a drug product's official indications in accordance with Health Canada's approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for Paxlovid. The Executive Officer's funding of drug products is informed by advice from expert committees that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products. Note: The funded treatment is one dose pack** for a treatment duration of 5 days. In exceptional circumstances, the funded treatment is two dose packs** for a treatment duration of 10 days based on prescriber clinical judgement in consultation with an infectious disease specialist. Pharmacy operators must obtain and retain appropriate documentation to support claims for such extended therapy. For guidance, prescribers may consult Ontario Health - Frequently Asked Questions on Antiviral Therapy for Adults with Mild to Moderate COVID-19 (April 2024). Coverage limit: ** Dose pack for DIN: 02524031 is package of 30 tablets divided in 5 daily-dose blister cards containing 4 nirmatrelvir tablets (150mg each) and 2 ritonavir tablets (100mg each). ** Dose pack for DIN: 02527804 is a package of 20 tablets divided in 5 daily-dose blister cards containing 2 nirmatrelvir tablets (150mg each) and 2 ritonavir tablets (100mg each). Coverage limit: LU Authorization Period: 5 days or 10 days to align with funded treatment duration. Reason for Use code 675 For the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in patients 18 to 64 years of age with at least 1 risk factor* associated with more severe COVID-19 outcomes with: - a positive result from direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing (either using rapid antigen test or PCR), and - symptoms present for 5 days or fewer. The risk of progression to severe COVID-19 depends on the quantity of underlying medical conditions and how controlled the medical conditions are. * When assessing risk factors, prescribers may want to consult Ontario Health Recommendations for Antiviral Therapy for Adults with Mild to Moderate COVID-19 (April 2024). Examples of risk factors include: Vaccination Status: - Have never received a COVID-19 vaccine Medical Conditions: - Active tuberculosis (treated or untreated) - Cerebrovascular disease - Chronic kidney disease, especially CKD stage 4 or 5 and dialysis - Chronic lung diseases, limited to: asthma, bronchiectasis, chronic obstructive pulmonary disease, interstitial lung disease, pulmonary embolism, pulmonary hypertension - Chronic liver diseases, limited to: cirrhosis, non-alcoholic fatty liver disease, alcoholic liver disease, autoimmune hepatitis - Cystic fibrosis - Diabetes mellitus, type 1 or type 2 - Disabilities and developmental delay, including Down syndrome - Heart conditions (e.g., heart failure, coronary artery disease, cardiomyopathies) - Mental health conditions, limited to: mood disorders (including depression), schizophrenia spectrum disorders - Neurologic conditions that cause an inability to control respiratory secretions or communicate disease progression (e.g., cognitive disorders such as Alzheimer-type dementia) - Obesity (body mass index above 30kg per m2) - Pregnancy or recent pregnancy (42 days post-partum/end of pregnancy) Note for consideration: Certain medical or social vulnerabilities may confer an increased risk of disease progression because affected individuals may experience challenges in recognizing, communicating or acting on progressive COVID-19 symptoms. People who are at a high risk of poor outcomes from COVID-19 based on social determinants of health should be considered priority populations for access to antivirals. Individuals at high risk include Indigenous people, Black people, other members of racialized communities; people experiencing intellectual, developmental, or cognitive disabilities; people who use substances regularly (e.g., alcohol); people who live with mental health conditions; and people who are underhoused. Paxlovid (DIN: 02527804) is intended for patients with renal impairment or on dialysis. If Paxlovid (DIN: 02524031) is being dispensed for such patients, it requires dose adjustment. Treatment decisions should be individualized based on the prescriber's assessment of patient risk because not all medical or social vulnerabilities carry the same risk. Pharmacists and prescribers should be informed of and stay current with a drug product's official indications in accordance with Health Canada's approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for Paxlovid. The Executive Officer's funding of drug products is informed by advice from expert committees that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products. Note: The funded treatment is one dose pack** for a treatment duration of 5 days. Coverage limit: ** Dose pack for DIN: 02524031 is package of 30 tablets divided in 5 daily-dose blister cards containing 4 nirmatrelvir tablets (150mg each) and 2 ritonavir tablets (100mg each). ** Dose pack for DIN: 02527804 is a package of 20 tablets divided in 5 daily-dose blister cards containing 2 nirmatrelvir tablets (150mg each) and 2 ritonavir tablets (100mg each). Coverage limit: LU Authorization Period: 5 days to align with funded treatment duration.
No interchangeable product listed in the Ontario extract
Paxlovid · DIN 02524031 Manufacturer: Pfizer Canada Inc.; listing date 2024-05-17 Health Canada: Marketed since 2022-01-18 · brand PAXLOVID · ATC J05AE30 NIRMATRELVIR AND RITONAVIR · form Tablet · route Oral · ingredients NIRMATRELVIR 150 MG, RITONAVIR 100 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Paxlovid: Formulary list price $1288.8800/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1288.8800 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101307 · Verify on the e-Formulary ↗ (DIN 02524031)

Source record
DIN 02524031: Paxlovid Raw flags: sec12=Y, sec3=Y Item: 081800412; group id 102; item number 0181; lccId 00391; manufacturer id PFI Source form: Tab-30 Pk; strength: 150mg & 100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1288.8800; ministry $1288.8800 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02524031 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101307
Shortage status: resolved shortage (ended 2024-11-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02524031
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Paxlovid · DIN 02527804 · 150mg & 100mg · tablets, 20-pack

Limited Use — Reason for Use code 673, 674, 675 required; Health Canada lists this DIN as Cancelled post market since 2026-03-16 — choose a marketed DIN from the same-category list.Discontinued 2026-03-16 · checked 2026-09-02
StatusLimited Use — Reason for Use code 673, 674, 675 required; Health Canada lists this DIN as Cancelled post market since 2026-03-16 — choose a marketed DIN from the same-category list.
Write on scriptLU code 673, 674, 675 (patient must meet the criteria below); Health Canada lists this DIN as Cancelled post market since 2026-03-16 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 673, 674, 675
Reason for Use code 673 For the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in patients 65 years of age or older with: - a positive result from direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing (either using rapid antigen test or PCR), and - symptoms present for 5 days or fewer. Paxlovid (DIN: 02527804) is intended for patients with renal impairment or on dialysis. If Paxlovid (DIN: 02524031) is being dispensed for such patients, it requires dose adjustment. Treatment decisions should be individualized based on the prescriber's assessment of patient risk because not all medical or social vulnerabilities carry the same risk. Prescribers should consult Ontario Health Recommendations for Antiviral Therapy for Adults with Mild to Moderate COVID-19 (April 2024). Pharmacists and prescribers should be informed of and stay current with a drug product's official indications in accordance with Health Canada's approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for Paxlovid. The Executive Officer's funding of drug products is informed by advice from expert committees that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products. Note: The funded treatment is one dose pack* for a treatment duration of 5 days. * Dose pack for DIN: 02524031 is package of 30 tablets divided in 5 daily-dose blister cards containing 4 nirmatrelvir tablets (150mg each) and 2 ritonavir tablets (100mg each). * Dose pack for DIN: 02527804 is a package of 20 tablets divided in 5 daily-dose blister cards containing 2 nirmatrelvir tablets (150mg each) and 2 ritonavir tablets (100mg each). Coverage limit: LU Authorization Period: 5 days to align with funded treatment duration. Reason for Use code 674 For the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in immunocompromised* patients 18 years of age or older regardless of vaccine status or prior COVID-19 infections with: - a positive result from direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing (either using rapid antigen test or PCR), and - symptoms present for 5 days or fewer. * Prescribers should consult Ontario Health Recommendations for Antiviral Therapy for Adults with Mild to Moderate COVID-19 (April 2024). Examples of immunocompromised include: - Advanced untreated human immunodeficiency virus (HIV) or treated HIV with a CD4 count equal or less than 200 per mm3 or CD4 fraction equal or less than 15% - Bone marrow or stem cell transplant - Solid organ transplant - Have active hematological malignancy or recently received treatment for hematological malignancy - E.g., have received treatment with any anti-CD20 agents or B-cell depleting agents in the last 2 years - Chimeric antigen receptor (CAR) T-cell therapy in the last 6 months - Treatment for cancer (including solid tumors), limited to: systemic therapy in the last 6 months (e.g., chemotherapy, molecular therapy, immunotherapy, targeted therapies, monoclonal antibodies, excluding those receiving adjunctive hormonal therapy only) or radiation therapy in the last 3 months - Prednisone use equal to or greater than 20mg/day (or corticosteriod equivalent) for 14 days or more, or other moderately or severely immunosuppressive therapies (e.g., alkylating agents) - Primary immunodeficiencies. For example: - Hypogammaglobulinemia - Combined immune deficiencies affecting T-cells - Immune dysregulation (e.g., familial hemophagocytic lymphohistiocytosis) - Type 1 interferon defects caused by a genetic primary immunodeficiency disorder or secondary to anti-interferon autoantibodies - Diagnosed by an immunologist and requires ongoing immunoglobulin replacement therapy (IVIg or SCIg) - Primary immunodeficiency with a confirmed genetic cause (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome) Paxlovid (DIN: 02527804) is intended for patients with renal impairment or on dialysis. If Paxlovid (DIN: 02524031) is being dispensed for such patients, it requires dose adjustment. Treatment decisions should be individualized based on the prescriber's assessment of patient risk because not all medical or social vulnerabilities carry the same risk. Pharmacists and prescribers should be informed of and stay current with a drug product's official indications in accordance with Health Canada's approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for Paxlovid. The Executive Officer's funding of drug products is informed by advice from expert committees that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products. Note: The funded treatment is one dose pack** for a treatment duration of 5 days. In exceptional circumstances, the funded treatment is two dose packs** for a treatment duration of 10 days based on prescriber clinical judgement in consultation with an infectious disease specialist. Pharmacy operators must obtain and retain appropriate documentation to support claims for such extended therapy. For guidance, prescribers may consult Ontario Health - Frequently Asked Questions on Antiviral Therapy for Adults with Mild to Moderate COVID-19 (April 2024). Coverage limit: ** Dose pack for DIN: 02524031 is package of 30 tablets divided in 5 daily-dose blister cards containing 4 nirmatrelvir tablets (150mg each) and 2 ritonavir tablets (100mg each). ** Dose pack for DIN: 02527804 is a package of 20 tablets divided in 5 daily-dose blister cards containing 2 nirmatrelvir tablets (150mg each) and 2 ritonavir tablets (100mg each). Coverage limit: LU Authorization Period: 5 days or 10 days to align with funded treatment duration. Reason for Use code 675 For the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in patients 18 to 64 years of age with at least 1 risk factor* associated with more severe COVID-19 outcomes with: - a positive result from direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing (either using rapid antigen test or PCR), and - symptoms present for 5 days or fewer. The risk of progression to severe COVID-19 depends on the quantity of underlying medical conditions and how controlled the medical conditions are. * When assessing risk factors, prescribers may want to consult Ontario Health Recommendations for Antiviral Therapy for Adults with Mild to Moderate COVID-19 (April 2024). Examples of risk factors include: Vaccination Status: - Have never received a COVID-19 vaccine Medical Conditions: - Active tuberculosis (treated or untreated) - Cerebrovascular disease - Chronic kidney disease, especially CKD stage 4 or 5 and dialysis - Chronic lung diseases, limited to: asthma, bronchiectasis, chronic obstructive pulmonary disease, interstitial lung disease, pulmonary embolism, pulmonary hypertension - Chronic liver diseases, limited to: cirrhosis, non-alcoholic fatty liver disease, alcoholic liver disease, autoimmune hepatitis - Cystic fibrosis - Diabetes mellitus, type 1 or type 2 - Disabilities and developmental delay, including Down syndrome - Heart conditions (e.g., heart failure, coronary artery disease, cardiomyopathies) - Mental health conditions, limited to: mood disorders (including depression), schizophrenia spectrum disorders - Neurologic conditions that cause an inability to control respiratory secretions or communicate disease progression (e.g., cognitive disorders such as Alzheimer-type dementia) - Obesity (body mass index above 30kg per m2) - Pregnancy or recent pregnancy (42 days post-partum/end of pregnancy) Note for consideration: Certain medical or social vulnerabilities may confer an increased risk of disease progression because affected individuals may experience challenges in recognizing, communicating or acting on progressive COVID-19 symptoms. People who are at a high risk of poor outcomes from COVID-19 based on social determinants of health should be considered priority populations for access to antivirals. Individuals at high risk include Indigenous people, Black people, other members of racialized communities; people experiencing intellectual, developmental, or cognitive disabilities; people who use substances regularly (e.g., alcohol); people who live with mental health conditions; and people who are underhoused. Paxlovid (DIN: 02527804) is intended for patients with renal impairment or on dialysis. If Paxlovid (DIN: 02524031) is being dispensed for such patients, it requires dose adjustment. Treatment decisions should be individualized based on the prescriber's assessment of patient risk because not all medical or social vulnerabilities carry the same risk. Pharmacists and prescribers should be informed of and stay current with a drug product's official indications in accordance with Health Canada's approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for Paxlovid. The Executive Officer's funding of drug products is informed by advice from expert committees that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products. Note: The funded treatment is one dose pack** for a treatment duration of 5 days. Coverage limit: ** Dose pack for DIN: 02524031 is package of 30 tablets divided in 5 daily-dose blister cards containing 4 nirmatrelvir tablets (150mg each) and 2 ritonavir tablets (100mg each). ** Dose pack for DIN: 02527804 is a package of 20 tablets divided in 5 daily-dose blister cards containing 2 nirmatrelvir tablets (150mg each) and 2 ritonavir tablets (100mg each). Coverage limit: LU Authorization Period: 5 days to align with funded treatment duration.
No interchangeable product listed in the Ontario extract
Paxlovid · DIN 02527804 Manufacturer: Pfizer Canada Inc.; listing date 2024-05-17 Health Canada: Cancelled post market since 2026-03-16 · brand PAXLOVID · ATC J05AE30 NIRMATRELVIR AND RITONAVIR · form Tablet · route Oral · ingredients NIRMATRELVIR 150 MG, RITONAVIR 100 MG · company Pfizer canada ulc · schedule Prescription
Check this DIN again · Health Canada product record

Paxlovid: Formulary list price $580.0000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $580.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101698 · Verify on the e-Formulary ↗ (DIN 02527804)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02527804). DIN 02527804: Paxlovid Raw flags: dinStatus=E, sec12=Y, sec3=Y Item: 081800413; group id 102; item number 0180; lccId 00391; manufacturer id PFI Source form: Tab-20 Pk; strength: 150mg & 100mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; DIN status E, meaning unconfirmed Source prices (unrounded): $580.0000; ministry $580.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02527804 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101698
Shortage status: discontinued (2026-03-16, reported by PFIZER CANADA ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02527804
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2026-03-16 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (08:18 Antivirals) and how they are covered

Matched class: 08:18 Antivirals

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABACAVIR & LAMIVUDINE & ZIDOVUDINE, ABACAVIR SULFATE, ABACAVIR SULFATE & LAMIVUDINE, BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE, CABOTEGRAVIR, CABOTEGRAVIR & RILPIVIRINE, COBICISTAT & ELVITEGRAVIR & EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, DARUNAVIR & COBICISTAT, DARUNAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, DELAVIRDINE MESYLATE, DOLUTEGRAVIR, DOLUTEGRAVIR & ABACAVIR & LAMIVUDINE, DOLUTEGRAVIR & RILPIVIRINE, DOLUTEGRAVIR SODIUM/LAMIVUDINE, DORAVIRINE, DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE, ELVITEGRAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR ALAFENAMIDE HEMIFUMARATE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR DISOPROXIL, EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, ETRAVIRINE, FOSAMPRENAVIR CALCIUM, GANCICLOVIR SODIUM, LAMIVUDINE & ZIDOVUDINE, MARAVIROC, NELFINAVIR MESYLATE, RALTEGRAVIR POTASSIUM, RILPIVIRINE HYDROCHLORIDE Some products covered without a code (check the product listing): ACYCLOVIR, ATAZANAVIR SULFATE, DARUNAVIR, EFAVIRENZ, LAMIVUDINE, NEVIRAPINE, VALACYCLOVIR 08:18 Antivirals

ATAZANAVIR SULFATE

· 12 products · General benefit (8), Off-Formulary Interchangeable, not an ODB benefit (4) · strengths: 150mg, 200mg, 300mg · Cap

DARUNAVIR

· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 600mg, 800mg · Tab

FOSAMPRENAVIR CALCIUM

· 2 products · General benefit · strengths: 50mg/mL, 700mg · Oral Susp, Tab

NELFINAVIR MESYLATE

· 2 products · General benefit · strengths: 250mg, 625mg · Tab

ABACAVIR & LAMIVUDINE & ZIDOVUDINE

· 2 products · General benefit · strengths: 300mg & 150mg & 300mg · Tab

ABACAVIR SULFATE

· 4 products · General benefit · strengths: 20mg/mL, 300mg · O/L, Tab

ABACAVIR SULFATE & LAMIVUDINE

· 7 products · General benefit · strengths: 600mg & 300mg · Tab

ACYCLOVIR

· 15 products · Listed, not a benefit (2), General benefit (13) · strengths: 200mg, 400mg, 800mg · Tab

BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE

· 1 products · General benefit · strengths: 50mg & 200mg & 25mg · Tab

CABOTEGRAVIR

· 3 products · General benefit · strengths: 200mg/mL, 30mg · Inj Sol-ER Susp 3mL Vial Kit Pk, Tab

CABOTEGRAVIR & RILPIVIRINE

· 2 products · General benefit · strengths: 200mg/mL & 300mg/mL · Inj Sol-2mL Kit, Inj Sol-3mL Kit

COBICISTAT & ELVITEGRAVIR & EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE

· 1 products · General benefit · strengths: 150mg & 150mg & 200mg & 300mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:18 and 40 more
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives, 08:40 Miscellaneous Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: hiv-1 infection
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: CABOTEGRAVIR, CABOTEGRAVIR & RILPIVIRINE, DORAVIRINE, EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE, EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, RALTEGRAVIR POTASSIUM CABOTEGRAVIR · General benefit 1 Indications VOCABRIA (cabotegravir tablets) is indicated, in combination with EDURANT (rilpivirine tablets), as a complete regimen for short-term treatment of human immunodeficiency virus type 1 (HIV-1) infection in patients, at least 12 years of age and weighing at least 35 kg, who are virologically stable and suppressed (HIV-1 RNA less than 50 copies/mL) as: • an oral lead-in to assess tolerability of cabotegravir prior to initiating CABENUVA • oral bridging therapy for missed CABENUVA injections CABENUVA (cabotegravir and rilpivirine extended release injectable suspensions) is indicated: • as a complete regimen for the treatment of HIV-1 infection in patients, at least 12 years of age and weighing at least 35 kg, to replace the current antiretroviral regimen in patients who are virologically stable and suppressed (HIV-1 RNA less than 50 copies/mL). 1.1 Pediatrics Pediatrics (≥ 12 and < 18 years of age): the use of VOCABRIA and CABENUVA in adolescent patients 12 years of age and older and weighing at least 35 kg is supported by the interim safety and pharmacokinetic data of an ongoing phase 1/2 open-label, non-comparative study in which oral and injectable cabotegravir or oral and injectable rilpivirine, each as a single agent, was administered in combination with other antiretroviral agents, and also by the pharmacokinetic data from studies with VOCABRIA, CABENUVA and oral and injectable rilpivirine use in adults (see 8.2.1 Clinical Trial Adverse Reactions-Pediatrics, 10.3 Pharmacokinetics, and 14 CLINICAL TRIALS; oral rilpivirine use refers to the EDURANT product monograph). PM: https://pdf.hres.ca/dpd_pm/00080949.PDF; date 2025-06-30; DIN 02497204; fetched 2026-09-10 Product monograph CABOTEGRAVIR & RILPIVIRINE · General benefit 1 Indications VOCABRIA (cabotegravir tablets) is indicated, in combination with EDURANT (rilpivirine tablets), as a complete regimen for short-term treatment of human immunodeficiency virus type 1 (HIV-1) infection in patients, at least 12 years of age and weighing at least 35 kg, who are virologically stable and suppressed (HIV-1 RNA less than 50 copies/mL) as: • an oral lead-in to assess tolerability of cabotegravir prior to initiating CABENUVA • oral bridging therapy for missed CABENUVA injections CABENUVA (cabotegravir and rilpivirine extended release injectable suspensions) is indicated: • as a complete regimen for the treatment of HIV-1 infection in patients, at least 12 years of age and weighing at least 35 kg, to replace the current antiretroviral regimen in patients who are virologically stable and suppressed (HIV-1 RNA less than 50 copies/mL). 1.1 Pediatrics Pediatrics (≥ 12 and < 18 years of age): the use of VOCABRIA and CABENUVA in adolescent patients 12 years of age and older and weighing at least 35 kg is supported by the interim safety and pharmacokinetic data of an ongoing phase 1/2 open-label, non-comparative study in which oral and injectable cabotegravir or oral and injectable rilpivirine, each as a single agent, was administered in combination with other antiretroviral agents, and also by the pharmacokinetic data from studies with VOCABRIA, CABENUVA and oral and injectable rilpivirine use in adults (see 8.2.1 Clinical Trial Adverse Reactions-Pediatrics, 10.3 Pharmacokinetics, and 14 CLINICAL TRIALS; oral rilpivirine use refers to the EDURANT product monograph). PM: https://pdf.hres.ca/dpd_pm/00080951.PDF; date 2025-06-30; DIN 02497220; fetched 2026-09-10 Product monograph DARUNAVIR · Listed, not a benefit (2), General benefit (6) 1 INDICATIONS Auro-Darunavir (darunavir), co-administered with 100 mg ritonavir, and with other antiretroviral agents, is indicated for the treatment of HIV-1 infection in patients ≥ 40 kg. PM: https://pdf.hres.ca/dpd_pm/00073833.PDF; date December 7, 2023; DIN 02486121; fetched 2026-09-10 Product monograph DORAVIRINE · General benefit 1 Indications PIFELTRO® (doravirine) is indicated, in combination with other antiretroviral medicinal products, for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older and weighing at least 35kg without past or present evidence of viral resistance to doravirine. 1.1 Pediatrics Pediatrics ( 12 to < 18 years of age): The safety and efficacy of PIFELTRO® in pediatric patients  12 years of age and weighing at least 35 kg receiving doravirine 100 mg once daily has been established (see 8.2.1 Clinical Trial Adverse Reactions – Pediatrics and 14 Clinical Trials). PM: https://pdf.hres.ca/dpd_pm/00081853.PDF; date not captured; DIN 02481545; fetched 2026-09-10 Product monograph EFAVIRENZ · Listed, not a benefit (1), General benefit (4) INDICATIONS AND CLINICAL USE Mylan-Efavirenz (efavirenz) is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents. PM: https://pdf.hres.ca/dpd_pm/00076879.PDF; date AUG 29, 2024; DIN 02381524; fetched 2026-09-10 Product monograph EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE · General benefit INDICATIONS AND CLINICAL USE TEVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR (efavirenz [EFV]/emtricitabine [FTC]/tenofovir disoproxil fumarate [TDF]) is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. PM: https://pdf.hres.ca/dpd_pm/00056758.PDF; date June 1, 2020; DIN 02393549; fetched 2026-09-10 Product monograph EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE · General benefit INDICATIONS AND CLINICAL USE Treatment of HIV-1 Infection TRUVADA is indicated in combination with other antiretroviral agents (such as non- nucleoside reverse transcriptase inhibitors or protease inhibitors) for the treatment of HIV-1 infection in adults. PM: https://pdf.hres.ca/dpd_pm/00046237.PDF; date July 5, 2018; DIN 02274906; fetched 2026-09-10 Product monograph NEVIRAPINE · Listed, not a benefit (2), General benefit (5) INDICATIONS AND CLINICAL USE AURO-NEVIRAPINE (nevirapine) is indicated as an alternative for:  treatment of HIV-1 infection in combination with other antiretroviral agents. PM: https://pdf.hres.ca/dpd_pm/00058912.PDF; date not captured; DIN 02318601; fetched 2026-09-10 Product monograph RALTEGRAVIR POTASSIUM · General benefit 1 INDICATIONS Adults ISENTRESS® and ISENTRESS HD® (raltegravir) are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients. 1.1 Pediatrics Pediatrics (2 - 18 years of age and weighing at least 7kg): ISENTRESS® is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in children and adolescents 2 years of age and older with body weight at least 7 kg. PM: https://pdf.hres.ca/dpd_pm/00073112.PDF; date November 9, 2007; DIN 02301881; fetched 2026-09-10 Product monograph TENOFOVIR DISOPROXIL · Limited Use, codes 517, 518, 519, 520, 521, 522 INDICATIONS AND CLINICAL USE HIV-1 Infection VIREAD (tenofovir disoproxil fumarate [TDF]) is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents in patients 12 years of age and older. PM: https://pdf.hres.ca/dpd_pm/00045932.PDF; date June 13, 2018; DIN 02247128; fetched 2026-09-10 Product monograph and 1 more Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1. Indications NORVIR (ritonavir) is indicated in combination with other antiretroviral agents for the treatment of HIV infection when therapy is warranted. 1.1. Pediatrics Pediatrics (2 to 16 years of age): NORVIR concentrations obtained after 350 to 400 mg/m² twice daily in pediatric patients were comparable to those obtained in adults receiving 600 mg (approximately 330 mg/m²) twice daily (see 10.3. Pharmacokinetics). The safety and effectiveness of NORVIR in pediatric patients below the age of 2 years have not been established. 1.2. Geriatrics Geriatrics (> 65 years of age): Clinical studies of NORVIR did not include sufficient numbers of subjects age 65 and over to determine whether they respond differently from younger subjects. In general, appropriate caution should be exercised in the administration and monitoring of NORVIR in elderly patients reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. https://pdf.hres.ca/dpd_pm/00085371.PDF PM date: 2026-07-14 Source product: NORVIR; DIN 02357593; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1. Indications KALETRA (lopinavir/ritonavir) is indicated in combination with other antiretroviral agents when therapy is warranted for the treatment of HIV-1 infection. The following points should be considered when initiating therapy with KALETRA: • The use of other active agents with KALETRA is associated with a greater likelihood of treatment response (see 14. Clinical Trials and 15. Microbiology) • Genotypic or phenotypic testing and/or treatment history should guide the use of KALETRA. The number of baseline lopinavir-associated substitutions affects the virologic response of KALETRA (see 15. Microbiology). 1.1. Pediatrics Pediatrics (6 months to 18 years of age): Based on a pediatric study, at week 24, the efficacy and safety with twice daily dosing in the pediatric population given KALETRA 100/25 mg tablets was consistent with the efficacy and safety findings in previous adult and pediatric studies using KALETRA twice daily (see 14.2. Study Results). The safety and pharmacokinetic profiles of KALETRA in pediatric patients below the age of 6 months have not been established. 1.2. Geriatrics Geriatrics (≥ 65 years of age): Clinica… https://pdf.hres.ca/dpd_pm/00085373.PDF PM date: 2026-07-14 Source product: KALETRA; DIN 02243644; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1. Indications PAXLOVID (nirmatrelvir tablets; ritonavir tablets) is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. PAXLOVID is not authorized: • For initiation of treatment in patients requiring hospitalization due to severe or critical COVID- 19. • For pre-exposure or post-exposure prophylaxis for prevention of COVID-19. • For use for longer than 5 consecutive days. 1.1. Pediatrics The safety and effectiveness of PAXLOVID have not been established in pediatric patients (<18 years of age). 1.2. Geriatrics Clinical studies of PAXLOVID include participants 65 years of age and older and their data contributes to the overall assessment of safety and efficacy (see 14 Clinical Trials). Of the total number of participants in the pivotal trial randomized to receive PAXLOVID (N=1,120), 13% were 65 years of age and older and 3% were 75 years of age and older. https://pdf.hres.ca/dpd_pm/00085971.PDF PM date: 2026-08-28 Source product: PAXLOVID; DIN 02524031; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Paxlovid · DIN 02527804 Shortage status: discontinued (2026-03-16, reported by PFIZER CANADA ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02527804

Check this DIN again